AI Article Synopsis

  • Tuberculosis is a major global health issue, especially in Ethiopia, where non-adherence to treatment presents significant challenges, and existing studies on this topic show mixed results.
  • A systematic review and meta-analysis of 13 studies found that approximately 21.29% of tuberculosis patients in Ethiopia do not adhere to their treatment, with regional variations in prevalence.
  • Key factors contributing to non-adherence included forgetfulness, fear of side effects from medication, long wait times at healthcare facilities, and the perceived distance to treatment centers.

Article Abstract

Background: Tuberculosis is a global public health problem. One of the overarching dilemmas and challenges facing most tuberculosis program is non-adherence to treatment. However, in Ethiopia there are few studies with variable and inconsistent findings regarding non-adherence to treatment for tuberculosis.

Methods: This systematic review and meta-analysis was conducted to determine the prevalence of non-adherence to tuberculosis treatment and its determinants in Ethiopia. Biomedical databases including PubMed, Google Scholar, Science Direct, HINARI, EMBASE and Cochrane Library were systematically and comprehensively searched. To estimate the pooled prevalence, studies reporting the prevalence of adherence or non-adherence to tuberculosis treatment and its determinants were included. Data were extracted using a standardized data extraction tool prepared in Microsoft Excel and transferred to STATA/se version-14 statistical software for further analyses. To assess heterogeneity, the Cochrane Q test statistics and I2 test were performed. Since the included studies exhibited high heterogeneity, a random effects model meta- analysis was used to estimate the pooled prevalence of non-adherence to tuberculosis treatment. Finally, the association between determinant factors and non-adherence to tuberculosis treatment was assessed.

Results: The result of 13 studies revealed that the pooled prevalence of non-adherence to tuberculosis treatment in Ethiopia was found to be 21.29% (95% CI: 15.75, 26.68). In the subgroup analysis, the highest prevalence was observed in Southern Nations and Nationalities of Ethiopia, 23.61% (95% CI: 21.05, 26.17) whereas the lowest prevalence was observed in Amhara region, 10.0% (95% CI: 6.48, 13.17.0;). Forgetfulness (OR = 3.22, 95% CI = 2.28, 4.53), fear side effect of the drugs (OR = 1.93, 95% CI = 1.37, 2.74), waiting time ≥ 1 hour during service (OR = 4.88, 95% CI = 3.44, 6.91) and feeling distance to health institution is long (OR = 5.35, 95% CI = 4.00, 7.16) were found to be determinants of non-adherence to tuberculosis treatment.

Conclusion: In this meta-analysis, the pooled prevalence of non-adherence to tuberculosis treatment in Ethiopia was high. Forgetfulness, fear of side effect of the drugs, long waiting time (≥1 hour) during service and feeling distance to health institution is long were the main risk factors for non-adherence to tuberculosis treatment in Ethiopia. Early monitoring of the side effects and other reasons which account for missing medication may increase medication adherence in patients with tuberculosis in Ethiopia.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328265PMC
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0210422PLOS

Publication Analysis

Top Keywords

non-adherence tuberculosis
32
tuberculosis treatment
28
treatment ethiopia
16
prevalence non-adherence
16
pooled prevalence
16
non-adherence
11
tuberculosis
11
treatment
10
prevalence
9
ethiopia
8

Similar Publications

An Evaluation of Medication Adherence in New Tuberculosis Cases in Ankara: A Prospective Cohort Study.

Healthcare (Basel)

November 2024

Department of Public Health, Faculty of Medicine, Hacettepe University, Ankara 06230, Türkiye.

Background/objectives: The objective of this study was to investigate the factors influencing adherence with tuberculosis medication therapy. Non-adherence can result in treatment failure, ongoing infectiousness, and the development of drug resistance. Therefore, understanding the reasons behind non-adherence is crucial for achieving the World Health Organization's target of 90% treatment success.

View Article and Find Full Text PDF

Piloting "From the Inside Out" - a toolkit addressing tuberculosis-related self-stigma.

BMC Glob Public Health

June 2024

Department of Public Health and Epidemiology, Royal College of Surgeons in Ireland (RCSI), 123 St Stephen's Green, Dublin 2, D02 YN77, Ireland.

Background: Self-stigma among people who have tuberculosis (TB) can contribute to non-adherence to medication and disengagement from care. It can manifest in feelings of worthlessness, shame, and guilt, leading to social withdrawal and disengagement from life opportunities. Self-stigma may also affect families of those who have TB, or healthcare workers who treat them.

View Article and Find Full Text PDF

Medical factors and non-medical factors account for a high number of difficulties in treating tuberculosis. This study aims to comprehensively examine the factors that contribute to failure in tuberculosis treatment. We searched for relevant articles in various databases, such as PubMed, ScienceDirect, ProQuest, Research Gate and Google Scholar.

View Article and Find Full Text PDF
Article Synopsis
  • HIV significantly affects neurocognitive function in Africa, leading to high prevalence rates of neurocognitive disorders, with Central and South Africa showing the highest impairment levels (around 49.33%).
  • Variability in neurocognitive impairment prevalence is influenced by factors like ART availability, healthcare infrastructure, and co-infections, emphasizing the need for targeted interventions.
  • Addressing this issue requires collaboration among healthcare providers, policymakers, and communities, focusing on education, early detection, improved resources, and research partnerships to better support individuals living with HIV.
View Article and Find Full Text PDF

Medication non-adherence remains a substantial obstacle in asthma care, prompting the exploration of novel therapeutic modalities that prioritize rapid symptom relief, anti-inflammatory activity, and facilitate patients' compliance. This task is well-served by the following new form of therapy: inhaled triple-combination medications ICS/LABA/LAMA (inhaled glucocorticosteroid/long-acting beta2-agonist/long-acting muscarinic antagonist). The integration of three medications within a singular inhalation device culminates in the reduction of the effective dose of the principal therapeutic agent for asthma management, namely ICS.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!